Chimerix (CMRX) announced that, following extensive dialogue with the FDA, the company plans to submit a complete new drug application, or NDA, seeking accelerated approval for dordaviprone as a treatment for recurrent H3 K27M-mutant diffuse glioma in the United States before year-end.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMRX: